Page 170 - Screening for Cervical Cancer: Systematic Evidence Review
P. 170
Chapter III: Results
Performance of Screening HPV* Testing for Detection of High-grade Abnormalities
True Neg Pos False LR LR NPV ll PPV ll Prev § Spec Positive Neg 0.3 15.0 99.6 17.6 1.4 95.1 145 2801 0.4 3.6 99.5 4.3 1.3 80.7 245 1024 0.1 16.7 99.9 17.2 1.2 94.3 96 1586 0.1 4.7 99.0 40.0 12.3 80.2 24 97 0.3 11.3 99.6 15.8 1.6 93.4 556 7859 0.1 8.0 98.2 53.0 12.3 89.0 108 873 0.2 1.5 95.5 24.4 17.3 41.3 121 85 0.5 2.4 96.8 13.3 6.0 74.5 52 152 0.3 2.1 96.7 19.0 10.0 61.6 740 1185 0.2 4.8 99.2 17.1 4.1 82.6 228 1081 0.2 4.0 98.5 23.4 7.2 78.7 1345 4962 0.2 4.2 98.5 23.3
Sens 73.8 68.8 95.2 94.1 74.8 88.4 90.7 61.5 80.9 83.9 84.4 83.7 81.6 HIV, human immunodeficiency virus, where + indicates participants with HIV infection and should be indicates those without infection.
False Neg 11 5 1 1 35 16 4 5 41 9 76 72 56
True Positive 31 11 20 16 104 122 39 8 174 47 410 371 249
Total N 2988 1285 1703 138 8554 1119 249 217 2140 1365 6793 6544 5425
Test Method SHARP # I** HC II HC HC I (HIV+ ) I HC HC II HC II (HIV + ) HC II** (HIV - ) II HC II HC Total all HC II HCII excluding HIV + HCII in populations with prevalence <10% ll PPV and NPV, positive and negative predictive value. ¶ Pos LR and Neg LR, positive and negative likelihood ratio. # SHARP, SHARP detection system.
Table 8. Article Cuzick et al., 1999 21 Petry et al., 1999 61 Shiffman et al., 2000 65 Womack et al., 2000 63 Womack et al., 2000 62 Wright et al., 2000 64 *HPV, human papilloma virus. Sens, sensitivity. Spec, specificity. § Prev, prevalence. **HC, hybrid capture. Physician collected samples.
71
